Apogee Therapeutics, Inc. (APGE) Insider Trading Activity
NASDAQ$39.74
Market Cap
$2.32B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
143 of 878
Rank in Industry
90 of 506
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
| $337M | ||
| $259M | ||
| $79M | ||
| $76M | ||
| $60M | ||
| $57M |
APGE Insider Trading Activity
APGE Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $990,775 | 1 | 5 |
Sells | $11,831,721 | 20 | 95 |
Related Transactions
| McKenna Mark C. | director | 1 | $990,775 | 0 | $0 | $990,775 |
| Henderson Jane | Chief Financial Officer | 0 | $0 | 1 | $289,560 | $-289,560 |
| Dambkowski Carl | Chief Medical Officer | 0 | $0 | 11 | $2.53M | $-2.53M |
| HENDERSON MICHAEL THOMAS | Chief Executive Officer | 0 | $0 | 8 | $9.01M | $-9.01M |
About Apogee Therapeutics, Inc.
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.
Insider Activity of Apogee Therapeutics, Inc.
Over the last 12 months, insiders at Apogee Therapeutics, Inc. have bought $990,775 and sold $11.83M worth of Apogee Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Apogee Therapeutics, Inc. have bought $25.5M and sold $11.83M worth of stock each year.
Highest buying activity among insiders over the last 12 months: McKenna Mark C. (director) — $990,775.
The last purchase of 20,000 shares for transaction amount of $990,775 was made by McKenna Mark C. (director) on 2024‑12‑12.
List of Insider Buy and Sell Transactions, Apogee Therapeutics, Inc.
| 2025-05-07 | Sale | Dambkowski Carl | Chief Medical Officer | 2,725 0.0047% | $35.75 | $97,419 | +8.26% | |
| 2025-04-02 | Sale | Dambkowski Carl | Chief Medical Officer | 3,860 0.0062% | $36.22 | $139,801 | -4.78% | |
| 2025-03-05 | Sale | HENDERSON MICHAEL THOMAS | Chief Executive Officer | 10,000 0.0161% | $30.15 | $301,511 | +19.15% | |
| 2025-03-05 | Sale | Dambkowski Carl | Chief Medical Officer | 1,590 0.0026% | $30.48 | $48,463 | +19.15% | |
| 2025-02-05 | Sale | HENDERSON MICHAEL THOMAS | Chief Executive Officer | 15,000 0.0257% | $40.58 | $608,700 | -11.61% | |
| 2025-02-05 | Sale | Dambkowski Carl | Chief Medical Officer | 3,520 0.006% | $40.69 | $143,229 | -11.61% | |
| 2025-01-08 | Sale | HENDERSON MICHAEL THOMAS | Chief Executive Officer | 15,000 0.0256% | $48.85 | $732,693 | -23.71% | |
| 2025-01-02 | Sale | Dambkowski Carl | Chief Medical Officer | 4,085 0.007% | $46.94 | $191,740 | -19.45% | |
| 2024-12-12 | McKenna Mark C. | director | 20,000 0.0375% | $49.54 | $990,775 | -11.91% | ||
| 2024-12-11 | Sale | Dambkowski Carl | Chief Medical Officer | 4,540 0.0075% | $48.76 | $221,363 | -19.69% | |
| 2024-12-04 | Sale | HENDERSON MICHAEL THOMAS | Chief Executive Officer | 15,000 0.0232% | $46.58 | $698,654 | -24.46% | |
| 2024-12-04 | Sale | Dambkowski Carl | Chief Medical Officer | 6,665 0.0102% | $46.07 | $307,057 | -24.46% | |
| 2024-11-06 | Sale | HENDERSON MICHAEL THOMAS | Chief Executive Officer | 15,000 0.0336% | $59.22 | $888,320 | -31.76% | |
| 2024-11-06 | Sale | Dambkowski Carl | Chief Medical Officer | 6,665 0.0149% | $59.12 | $394,041 | -31.76% | |
| 2024-10-02 | Sale | HENDERSON MICHAEL THOMAS | Chief Executive Officer | 40,000 0.0851% | $56.23 | $2.25M | -28.03% | |
| 2024-10-02 | Sale | Dambkowski Carl | Chief Medical Officer | 6,665 0.0142% | $56.26 | $374,954 | -28.03% | |
| 2024-09-04 | Sale | HENDERSON MICHAEL THOMAS | Chief Executive Officer | 40,000 0.0721% | $47.62 | $1.9M | -8.07% | |
| 2024-09-04 | Sale | Dambkowski Carl | Chief Medical Officer | 6,665 0.012% | $47.56 | $316,969 | -8.07% | |
| 2024-08-23 | Sale | Henderson Jane | Chief Financial Officer | 6,000 0.011% | $48.26 | $289,560 | -8.35% | |
| 2024-08-07 | Sale | HENDERSON MICHAEL THOMAS | Chief Executive Officer | 40,000 0.0615% | $40.62 | $1.62M | +8.88% |
Total: 22
*Gray background shows transactions not older than one year
Insider Historical Profitability
50.02%
| HENDERSON MICHAEL THOMAS | Chief Executive Officer | 1292987 2.2152% | $51.38M | 0 | 8 | |
| Dambkowski Carl | Chief Medical Officer | 244448 0.4188% | $9.71M | 0 | 11 | |
| Henderson Jane | Chief Financial Officer | 200871 0.3441% | $7.98M | 0 | 1 | |
| McKenna Mark C. | director | 20000 0.0343% | $794,800.00 | 1 | 0 | |
| Fairmount Funds Management LLC | director | 1992734 3.414% | $79.19M | 1 | 0 | +50.02% |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$20,297,544 | 73 | 103.06% | $2.11B | |
$11,588,217 | 69 | 42.07% | $2.88B | |
$1,376,668 | 53 | 18.46% | $2.2B | |
$224,368,761 | 42 | 28.26% | $2.24B | |
$140,165,669 | 33 | 85.24% | $2.38B | |
$1,275,975,557 | 32 | 19.44% | $2.88B | |
$5,066,938 | 27 | 26.38% | $2.27B | |
$1,801,511 | 23 | 18.58% | $2.1B | |
$128,181,928 | 16 | 18.84% | $2.83B | |
$174,105,409 | 15 | 10.88% | $2.17B | |
$70,151,579 | 12 | 22.57% | $2.98B | |
$91,269,919 | 12 | 12.86% | $2.9B | |
$1,248,715 | 10 | 5.66% | $2.3B | |
$35,908,794 | 10 | 126.31% | $2.74B | |
$117,959,652 | 9 | -12.47% | $2.45B | |
$1,711,150 | 9 | 31.59% | $3.11B | |
$55,713,031 | 8 | -0.36% | $2.22B | |
$276,224 | 2 | -7.04% | $2.11B | |
Apogee Therapeutics, Inc. (APGE) | $49,999,992 | 1 | 50.02% | $2.32B |
APGE Institutional Investors: Active Positions
| Increased Positions | 90 | +56.25% | 7M | +12.78% |
| Decreased Positions | 67 | -41.88% | 6M | -9.84% |
| New Positions | 40 | New | 4M | New |
| Sold Out Positions | 21 | Sold Out | 2M | Sold Out |
| Total Postitions | 183 | +14.38% | 58M | +2.93% |
APGE Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Vr Adviser, Llc | $340,752.00 | 18.46% | 8.49M | 0 | 0% | 2024-12-31 |
| Fmr Llc | $300,875.00 | 16.3% | 7.5M | -3,100 | -0.04% | 2024-12-31 |
| Wellington Management Group Llp | $181,237.00 | 9.82% | 4.52M | -297,037 | -6.17% | 2024-12-31 |
| Blackrock, Inc. | $116,782.00 | 6.33% | 2.91M | -134,129 | -4.41% | 2025-03-31 |
| Rtw Investments, Lp | $108,809.00 | 5.9% | 2.71M | +<1 | 0% | 2024-12-31 |
| Driehaus Capital Management Llc | $104,525.00 | 5.66% | 2.61M | +71,703 | +2.83% | 2024-12-31 |
| Vanguard Group Inc | $84,156.00 | 4.56% | 2.1M | -29,445 | -1.38% | 2024-12-31 |
| Fairmount Funds Management Llc | $82,192.00 | 4.45% | 2.05M | 0 | 0% | 2024-12-31 |
| Ra Capital Management, L.P. | $62,968.00 | 3.41% | 1.57M | -392,372 | -20% | 2024-12-31 |
| Braidwell Lp | $61,799.00 | 3.35% | 1.54M | -102,864 | -6.26% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Price to Earnings
Price/Earnings to Growth
Price to Sales
Price to Book
Price/Free Cash Flow
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.